Mischa A. Houtkamp
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.
Journal: Molecular cancer therapeutics
Published: January 13, 2026
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Journal: Molecular cancer therapeutics
Published: May 17, 2023
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Journal: Life science alliance
Published: April 13, 2022
Systematic study of tissue factor expression in solid tumors.
Journal: Cancer reports (Hoboken, N.J.)
Published: January 07, 2022
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Journal: Cancer research
Published: February 05, 2020
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
Journal: Molecular cancer therapeutics
Published: June 20, 2018
Three-dimensional histologic validation of high-resolution SPECT of antibody distributions within xenografts.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 02, 2014
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Journal: Cancer research
Published: December 28, 2013
Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor.
Journal: PloS one
Published: November 15, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026